Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of canagliflozin on myocardial fatty acid metabolism using BMIPP SPECT (ISMFAM)
jRCT1041190002Recruiting
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of canagliflozin in type 2 diabetes mellitus (T2DM), heart failure (HF) and diastolic dysfunction (2 arms). Primary endpoints: Myocardial fatty acid metabolism at 6 months and Myocardial fatty acid metabolism at 12 months. Started Apr 2019; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)diastolic dysfunction
Beyond the preview
Go deeper on jRCT1041190002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041190002.